| Trial | control | p<0.05 | harm | NS |
|---|
| VA-HIT, 1999 | vs placebo | coronary events 0.80 [0.68; 0.94] MI non fatal 0.80 [0.65; 0.97] cardiovascular events 0.78 [0.68; 0.90] | | Pancreatitis 1.00 [0.06; 16.01] all cause deaths 0.90 [0.76; 1.08] coronary deaths 0.79 [0.61; 1.02] décès par cancer 0.88 [0.60; 1.31] Cancers mortels et non mortels 0.91 [0.72; 1.14] stroke (fatal et non fatal) 0.76 [0.55; 1.07] cardiac death 0.79 [0.61; 1.02] non cardiovascular death 1.10 [0.84; 1.44] |
| Helsinki (HHS), 1987 | vs placebo | coronary events 0.66 [0.48; 0.92] MI non fatal 0.63 [0.44; 0.91] | | Pancreatitis 0.50 [0.12; 1.98] all cause deaths 1.02 [0.67; 1.54] coronary deaths 0.73 [0.37; 1.46] décès par cancer 0.99 [0.43; 2.29] cardiac death 0.73 [0.37; 1.46] non cardiovascular death 1.24 [0.73; 2.12] |
| HHS (Frick)(secondary prev subgroup), 1993 | vs placebo | | | all cause deaths 1.61 [0.80; 3.27] cardiac death 2.17 [0.95; 4.95] non cardiovascular death 0.51 [0.09; 2.76] |
| HHS (diabetic sub group), 1987 | vs placebo | | | |
| VA-HIT (diabetic sub group), 1999 | vs placebo | | | Critère de jugement principal de l'étude 0.00 [NaN; NaN] Cv events (CV death, MI, stroke) 0.00 [NaN; NaN] |
| LOCAT, 1997 | vs placebo | | | coronary events 1.01 [0.36; 2.81] |
| Trial | Treatments | Patients | Method |
|---|
| VA-HIT, 1999 | gemfibrozil 1.2g daily (n=1264) vs. placebo (n=1267) | men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less | double blind Parallel groups Sample size: 1264/1267 Primary endpoint: nonfatal myocardial infarction or death from coronary causes FU duration: 5.1 years |
| Helsinki (HHS), 1987 | gemfibrozil 1,2 g/d (n=2046) vs. placebo (n=2035)
| asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter]
| double blind Parallel groups Sample size: 2046/2035 Primary endpoint: CHD events FU duration: 5 years
|
| HHS (Frick)(secondary prev subgroup), 1993 | gemfibrozil 600 mg twice daily (n=311) vs. placebo (n=317) | individuals who exhibited symptoms and signs of possible coronary heart disease | double blind Parallel groups Sample size: 311/317 Primary endpoint: cardiac events FU duration: 5.0 years |
| HHS (diabetic sub group), 1987 | gemfibrozil 600mg twice daily (n=135) vs. placebo (n=0) | asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter | double blind Sample size: 135/0 Primary endpoint: FU duration: |
| VA-HIT (diabetic sub group), 1999 | gemfibrozil 1200 mg per day (n=309) vs. placebo (n=318) | men with coronary heart disease, an HDL cholesterol
level of 40 mg per deciliter (1.0 mmol per liter)
or less, and an LDL cholesterol level of 140 mg
per deciliter (3.6 mmol per liter) or less. | double blind Parallel groups Sample size: 309/318 Primary endpoint: FU duration: 5.1 y |
| LOCAT, 1997 | gemfibrozil 1200 mg/d (n=197) vs. placebo (n=198) | post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L | double blind Parallel groups Sample size: 197/198 Primary endpoint: diameters FU duration: 32 months |
